Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Remicade Sales Aid Makes Misleading Efficacy Claims, FDA Tells J&J

This article was originally published in The Pink Sheet Daily

Executive Summary

Sales aid improperly suggests the TNF-inhibitor can reverse or heal the disease process in patients with early rheumatoid arthritis, an FDA ad division “untitled” letter states. Agency also cites the promotion for omitting risk information. Centocor says the sales aid has not been used since October.

You may also be interested in...



Rheumatoid Arthritis Therapy “Healing” Evidence Lacks Precision, FDAer Says

Evidence of structural damage healing by rheumatoid arthritis agents has been incorrectly interpreted in some cases, FDA Medical Team Leader Siegel says. Radiographic signs of healing are often “statistical noise” or “an imprecision of readings.”

Rheumatoid Arthritis Therapy “Healing” Evidence Lacks Precision, FDAer Says

Evidence of structural damage healing by rheumatoid arthritis agents has been incorrectly interpreted in some cases, FDA Medical Team Leader Siegel says. Radiographic signs of healing are often “statistical noise” or “an imprecision of readings.”

Enbrel TV Ad Highlighting "Breakthrough Therapy" Draws FDA Warning Letter

Center for Drug Evaluation & Research ad review division says Amgen's commercial overstates the TNF-inhibitor's effectiveness, fails to communicate the limitations of the indication and minimizes risk. Amgen pulls the commercial from its media schedule in the wake of the agency's letter.

Topics

UsernamePublicRestriction

Register

PS061544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel